Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update

Autolus Therapeutics plc (NASDAQ:AUTL) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 8,630,000 shares, an increase of 12.4% from the December 15th total of 7,680,000 shares. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is currently 4.7 days.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AUTL shares. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Friday, November 15th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $10.40.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors have recently bought and sold shares of the company. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at about $43,000. Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the third quarter valued at approximately $51,000. Arkadios Wealth Advisors purchased a new position in Autolus Therapeutics in the fourth quarter worth approximately $47,000. Herbst Group LLC acquired a new position in Autolus Therapeutics during the 3rd quarter worth approximately $91,000. Finally, Avanza Fonder AB purchased a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $75,000. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Performance

NASDAQ:AUTL opened at $2.22 on Monday. The company has a fifty day moving average of $2.70 and a two-hundred day moving average of $3.56. Autolus Therapeutics has a fifty-two week low of $2.07 and a fifty-two week high of $7.37. The stock has a market capitalization of $590.72 million, a PE ratio of -1.83 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period last year, the firm earned ($0.26) EPS. Research analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.